Media statement: CEO’s appointment to HTA Review Reference Committee

14 March 2023: CEO of Medicines Australia, Elizabeth de Somer, has been appointed as the medicines industry representative on the Health Technology Assessment (HTA) Review Reference Committee.

The appointment was made today by the Minister for Health and Aged Care, the Hon. Mark Butler MP, which recognises Ms de Somer’s understanding of the issues, extensive industry experience, willingness to work collaboratively with all interested stakeholders, and commitment to reforming HTA in the best interest of all Australians.

“It is an honour to represent the medicines industry and take part in ensuring the reforms needed to speed up patient access to innovative medicines,” Ms de Somer said.

This position on the HTA Review Reference Committee was previously held by John Young, who has recently been appointed to the Novartis Board and has advised is unable to continue to serve the Committee in a voluntary capacity. Ms de Somer steps immediately into this role and thanked Mr Young for his service to date.

“On behalf of the Medicines Australia Board and the medicines industry, I wish to thank John for his exemplary contribution to the HTA Review Reference Committee and wish him all the best with his new role,” Ms de Somer said.

“John is a globally experienced industry leader and Medicines Australia is extremely pleased with what he has achieved on behalf of the medicines industry and will continue through a prominent and important Board position.

“The HTA Review is a crucial step in improving access to innovative medicines for all Australians.

“Success will hinge on a strong voice for reform and a collaborative approach – I intend to bring both to this important appointment,” she said.


For further information or media interviews, please contact:
Chrystianna Moran – 0424 995 118 /